Izmir Biomedicine and Genome Center

What Izmir Biomedicine and Genome Center does

Izmir Biomedicine and Genome Center (IBG) is a public Thematic Research Center established under Turkish Law No. 6550 and affiliated with Dokuz Eylül University in Balçova, İzmir. Founded in 2014 and operationally active since January 2018, IBG operates Turkey's largest life sciences research infrastructure — a 22,500 m² facility with 8,250 m² of laboratory space spread across seven floors. The center conducts research and development across cancer, genomics, bioinformatics, stem cells, immunology, infectious diseases, neuroscience, and bioengineering, and is explicitly tasked with reducing Turkey's dependence on foreign pharmaceuticals and vaccines through domestic biotechnological product development.

IBG operates an integrated platform architecture spanning the full R&D-to-commercialization continuum. Core platforms include IBG-NEVCELL (GMP-certified cell therapy manufacturing producing mesenchymal stem cells and tissue engineering products in 655 m² of Class B/C clean rooms), IBG-FARMA (biotechnological drug development), IBG-Biobank (biological sample management with ISO 20387 accreditation pending), and a Drug Analysis and Control Laboratory with Turkey's first GLP certification. Supporting these are specialized research units offering optical and electron microscopy, flow cytometry and cell sorting, histopathology, Simoa-based biomarker analysis, bioinformatics, a Zebrafish Facility (operating since 2016), and a Vivarium. The center also maintains a Business Development and Commercialization Unit handling IP management, licensing, and technology transfer.

IBG's revenue model blends government core funding and competitive grants (TÜBİTAK, TÜSEB, Ministry of Health, EU Horizon 2020), fee-based research services to academic and private-sector users, training and certification courses (€200–€45,000 TL range), and strategic industry partnerships with pharmaceutical and biotechnology companies including Merck, VSY Biotechnology, and Nobel Pharmaceuticals. Customers span academic and clinical researchers (primary), pharmaceutical/biotech companies, and government regulatory agencies. The center's regulatory stack — GLP, GMP, ISO 9001:2018, KVKK compliance, and pending ISO 20387 — combined with international collaborations (Oxford University, EMBL, ICGEB, BBMRI-ERIC, ERDERA, STEM-CORE) positions it as Turkey's anchor life sciences research infrastructure.

Name

Izmir Biomedicine and Genome Center

Legal name

İzmir Biyotıp ve Genom Merkezi

Website

https://ibg.edu.tr

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Izmir Biomedicine and Genome Center (IBG) is a Turkish public Thematic Research Center operating the country's largest life sciences infrastructure (22,500 m²), providing GMP cell therapy manufacturing, GLP drug analysis, biobanking, and biomedical research services to academic, pharmaceutical, and government clients.

Ownership category

akta.pro rank

Product category

Biomedical and Genomics Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Management, Scientific, and Technical Consulting Services (5416)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Pharmaceutical Preparations (2834)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Biomedical research services
• Genomics and life sciences
• GMP cell therapy manufacturing
• GLP drug analysis services
• Preclinical research infrastructure

Headquarters

HQ city

Balçova

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Government Funding and Research Grants: IBG operates primarily through public funding and competitive research grants from Turkish government agencies including TÜBİTAK, TÜSEB, and Ministry of Health
2. Research Services: Fee-based research support services offered to internal and external researchers including facility usage, equipment access, bioinformatics analysis, and biomarker testing
3. Training and Education: Revenue generated from training courses including Experimental Animal Use Certificate courses, specialized workshops, and educational programs with fees ranging from 200 EUR to 11,000 TL
4. Zebrafish Facility Services: Fee-based services including facility management training, fish sales, embryo sales, microscopy usage, toxicology analysis, and project-based consulting

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

IBG is Turkey's first Thematic Research Center providing integrated biomedical and genomic research services across multiple platforms. Core offerings include GMP-certified cell therapy manufacturing (IBG-NEVCELL), biotechnological drug development (IBG-FARMA), biobanking (IBG-Biobank), GLP-compliant preclinical drug analysis, and specialized research support units covering zebrafish models, optical/electron microscopy, flow cytometry, histopathology, Simoa biomarker analysis, and bioinformatics. The center also delivers certificate training programs, technology transfer, and IP commercialization support to academic and industry clients.

Product overview

Izmir Biomedicine and Genome Center (İBG) operates as Turkey's first Thematic Research Center, offering a comprehensive portfolio of biomedical and genomic research services through an integrated platform structure. The core offerings include IBG-NEVCELL (a GMP-certified cell therapy platform producing mesenchymal stem cells and tissue engineering products), the IBG-FARMA Platform for biotechnological drug development, and the IBG-Biobank Platform for biological sample management. Supporting these are specialized research units including GLP-certified drug analysis laboratory, zebrafish facility, optical imaging, flow cytometry, electron microscopy, histopathology, biomarker analysis (Simoa), and bioinformatics services. The center also provides technology transfer and commercialization support through its Business Development Unit. The facility spans 22,500 m2 with 8,250 m2 of laboratory space, conducting research in cancer, genomics, stem cells, immunology, neuroscience, and bioengineering.

Differentiator

Problem solved

Functional benefit

Brands

• NEVCELL: Cell therapy platform producing GMP-certified cellular treatment products for clinical applications.
• İBG-FARMA
• İBG-Biyobanka
• İBG Bilim Madalyası

Products and services

• IBG-NEVCELL (GMP Cell Therapy Platform)

Quantifiable outcome

• 46 high-impact scientific publications within first year of operations
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered major, flagship and core.

• Oxford UniversitymajorStrategic or Co-development Partner · 21 February 2025Healthcare research collaboration between IBG and Oxford University research institutions for advancing scientific research
• International Centre for Genetic Engineering and Biotechnology (ICGEB)majorStrategic or Co-development Partner · 1 January 2025Co-organization of international training course on Latest Technologies in Genome Editing and Assisted Reproductive Techniques at IBG with 200 EUR registration fee and scholarship opportunities
• EU-funded STEM-CORE ProjectmajorStrategic or Co-development Partner · 1 January 2025IBG partnership in EU-funded STEM-CORE project supporting science education and research collaboration
• MerckflagshipStrategic or Co-development Partner · 20 November 2019Collaboration for biotechnology drug development including laboratory infrastructure setup, technology transfer, knowledge sharing, and personnel training for developing biotechnological pharmaceuticals
• Dokuz Eylül Üniversitesi (DEU)coreStrategic or Co-development Partner · 1 January 2014Founding institution relationship; IBG established within DEU campus as Turkey's first Thematic Research Center under Law No. 6550; provides institutional infrastructure and academic integration
• Ministry of Health (Sağlık Bakanlığı)coreStrategic or Co-development PartnerGovernment ministry overseeing healthcare policy; TİTCK (Turkish Medicines and Medical Devices Agency) conducts GMP inspections of NEVCELL facility
• Turkish Accreditation Agency (TÜRKAK)coreOthersNational accreditation body conducting ISO 20387 biobank accreditation evaluation and GLP certification assessments for IBG facilities
• EMBL (European Molecular Biology Laboratory)majorStrategic or Co-development PartnerInternational collaboration on antibiotic resistance research (Barabas Lab with Karaca Lab) resulting in publication in Cell journal on transposase-DNA complex structures
• ERDERA (European Rare Disease Research Association)majorStrategic or Co-development PartnerIBG participation in ERDERA project bringing together rare disease stakeholders in Turkey for collaborative research initiatives

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• European Molecular Biology Laboratory (EMBL): Intergovernmental life sciences research organization with which İBG has active collaboration (Barabas/Karaca Lab on transposase-DNA published in Cell). Comparable as a publicly funded, basic-to-translational molecular biology research institution with shared service platforms.
• TÜBİTAK Marmara Research Center (MAM): Turkey's largest government-funded multidisciplinary R&D center under TÜBİTAK. Highly comparable to İBG as a state-affiliated research institution providing lab services, infrastructure access, and applied science funding across life sciences and materials in Turkey.
• International Centre for Genetic Engineering and Biotechnology (ICGEB): UN-system research organization running training programs in genetic engineering and biotechnology. Direct strategic partner co-organizing training courses at İBG and operationally comparable as a public-sector molecular biology and biotech capacity-builder.
• Bilkent UNAM (National Nanotechnology Research Center): Turkey's first thematic research center under Law No. 6550 at Bilkent University. Shares the same legal/governance framework as İBG, with comparable centralized research infrastructure, technology transfer mandate, and government funding model.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO offering discovery, biologics development, and testing services. Comparable to İBG's combined biopharmaceutical development (IBG-FARMA), biobanking, and GLP testing capabilities, though operating at global scale.
• Charles River Laboratories: Global CRO/CDMO providing preclinical research, GLP toxicology, and biologics services. Comparable to İBG across its GLP-certified Drug Analysis Laboratory and biopharmaceutical R&D platforms, though at much greater scale and commercial breadth.
• Eurofins Scientific: Global contract laboratory services provider across pharmaceutical, genomic, and clinical diagnostics testing. Comparable to İBG's fee-based laboratory service offerings (drug analysis, biomarker Simoa, flow cytometry, biobanking).
• Lonza Group (Cell & Gene Therapy CDMO): Global leader in cell and gene therapy contract manufacturing. Comparable to İBG's NEVCELL platform as a GMP-certified cell therapy manufacturing services provider, though at vastly greater global scale and with broader regulatory approval coverage.
• Catalent (Cell Therapy Manufacturing): Large-scale CDMO offering cell therapy development and GMP manufacturing services. Comparable to NEVCELL in cell therapy manufacturing, with broader geographic coverage and larger commercial pipeline.

Regional players

• Hacettepe University Research Centers: Major Turkish academic medical research complex with overlapping capabilities in genomics, clinical diagnostics, and translational biomedicine. Comparable as a domestic Turkish biomedical research institution competing for talent and grants, though without İBG's consolidated thematic center status.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/cakanzebrafishlab
• Xx.com/ibgcenter

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Izmir Biomedicine and Genome Center